SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Regeneron Pharmaceuticals

473

Regeneron Pharmaceuticals

REGN

The biopharmaceutical company develops and manufactures medicines concerning a range of illnesses, including asthma, pain, cancer, and infectious diseases.

Looking for leads, investment insights, or competitive intelligence?

CEO

Leonard S. Schleifer

CEO Title

President, Chief Executive Officer & Director

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Tarrytown, N.Y.

Years on Fortune 500 List

1

Employees

6,200

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$5,87220.8%
Profits ($M)$1,198.533.8%
Assets ($M)$8,764
Total Stockholder Equity ($M)$6,144
Market Value — as of March 29, 2018 ($M)$37,087
Profit Ratios
Profit as % of Revenues20.4%
Profits as % of Assets13.7%
Profits as % of Stockholder Equity19.5%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)10.34
EPS % Change (from 2016)34.3%
EPS % Change (5 year annual rate)8.9%
EPS % Change (10 year annual rate)-
Total Return
Total Return to Investors (2017)2.4%
Total Return to Investors (5 year, annualized)17.1%
Total Return to Investors (10 year, annualized)31.6%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Regeneron Pharmaceuticals

The Diseases We Aren't Curing—And Why

Drug makers are flocking to certain treatment types. Why do others get left behind?

Read More →
Could a Vaccine Prevent High Cholesterol and Heart Disease?

Scientists are ready to move an experimental treatment into phase 1 trials.

Read More →
Trump's Proposed Science Cuts Could Devastate Future Generations, Pharma Expert Says

“We should only be working on two things, health and the freaking environment.”

Read More →
Pharma Executives Aren't Excited About Trump's Plans to Ease FDA Regulation

They say a robust review process is needed to convince doctors and insurers new drugs have value.

Read More →